Apr 11 |
Oncolytics seeking FDA meeting to discuss registration-enabling study
|
Apr 11 |
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
|
Apr 2 |
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference
|
Mar 10 |
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript
|
Mar 9 |
Oncolytics Biotech, Inc. (ONCY) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Oncolytics Biotech GAAP EPS of -$0.05 beats by $0.06
|
Mar 7 |
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
|
Mar 7 |
Earnings Scheduled For March 7, 2024
|
Mar 6 |
Oncolytics Biotech Q4 2023 Earnings Preview
|
Mar 6 |
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
|